他汀类降脂治疗降低低密度脂蛋白胆固醇强度与卒中二级预防的关联:随机临床试验的荟萃分析
该荟萃分析纳入11项随机临床试验共20163例卒中患者,比较强化与次强化他汀类降脂治疗。强化治疗与复发性卒中风险降低相关(绝对风险8.1% vs 9.3%;RR 0.88;95%CI 0.80-0.96),在有动脉粥样硬化证据的患者中获益更明显,但出血性卒中风险增加。
要点
- 强化他汀类降脂治疗与复发性卒中风险降低相关(RR 0.88;95%CI 0.80-0.96)。
- 有动脉粥样硬化证据者强化治疗获益更明显(RR 0.79;95%CI 0.69-0.91)。
- 强化他汀类降脂治疗与出血性卒中风险增加相关。
核心结论
- 强化他汀类降脂治疗降低复发性卒中风险的获益与风险可能比次强化治疗更有利,尤其对于有动脉粥样硬化证据的患者。
研究设计与样本
- 随机临床试验的荟萃分析,最终纳入11项试验共20163例卒中患者(男13518例[67.0%];平均[SD]年龄64.9[3.7]岁)。
- 检索PubMed、Embase、Cochrane中央对照试验注册库和ClinicalTrials.gov,检索时间从1970年1月1日至2021年7月31日。
- 采用PRISMA报告规范提取数据并评估数据质量与有效性,以相对风险(RR)及95%CI作为关联指标。
主要发现
- 强化他汀类降脂治疗与复发性卒中风险降低相关(绝对风险8.1% vs 9.3%;RR 0.88;95%CI 0.80-0.96)。
- 不同降脂策略间获益无差异(他汀 vs 无他汀:RR 0.90;95%CI 0.81-1.01;更多他汀或依折麦布 vs 更少他汀或依折麦布:RR 0.77;95%CI 0.62-0.96;PCSK9抑制剂联合他汀 vs 安慰剂联合他汀:RR 0.90;95%CI 0.71-1.15;交互作用P=0.42)。
- 强化他汀类降脂治疗与主要心血管事件风险降低相关,但与出血性卒中风险增加相关。
- 在有动脉粥样硬化证据的试验中强化治疗与复发性卒中风险降低相关(RR 0.79;95%CI 0.69-0.91),在多数患者无动脉粥样硬化证据的试验中未观察到(RR 0.95;95%CI 0.85-1.07;交互作用P=0.04)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The benefits and risks associated with intensive low-density lipoprotein cholesterol (LDL-C)-lowering statin-based therapies to lessen the risk of recurrent stroke have not been established. OBJECTIVE: To conduct a meta-analysis of randomized clinical trials to evaluate the association of more intensive vs less intensive LDL-C-lowering statin-based therapies with outcomes for patients with ischemic stroke. DATA SOURCES: PubMed, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov were searched from January 1, 1970, to July 31, 2021. STUDY SELECTION: This meta-analysis included randomized clinical trials that compared more intensive vs less intensive LDL-C-lowering statin-based therapies and recorded the outcome of recurrent stroke among patients with stroke. DATA EXTRACTION AND SYNTHESIS: The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline was used for abstracting data and assessing data quality and validity. Relative risk (RR) with 95% CI was used as a measure of the association of more intensive vs less intensive LDL-C lowering with primary and secondary outcomes. MAIN OUTCOMES AND MEASURES: The primary outcome was recurrent stroke, and the secondary outcomes were major cardiovascular events and hemorrhagic stroke. RESULTS: The final analysis included 11 randomized clinical trials with 20 163 patients (13 518 men [67.0%]; mean [SD] age, 64.9 [3.7] years) with stroke. The mean follow-up was 4 years (range, 1-6.1 years). Pooled results showed that more intensive LDL-C-lowering statin-based therapies were associated with a reduced risk of recurrent stroke compared with less intensive LDL-C-lowering statin-based therapies (absolute risk, 8.1% vs 9.3%; RR, 0.88; 95% CI, 0.80-0.96) and that the benefit associated with these LDL-C-lowering therapies was not different among LDL-C-lowering strategies (statins vs no statins: RR, 0.90; 95% CI, 0.81-1.01; more statins or ezetimibe vs less statins or ezetimibe: RR, 0.77; 95% CI, 0.62-0.96; and proprotein convertase subtilisin/kexin type 9 inhibitors plus statins vs placebo plus statins: RR, 0.90; 95% CI, 0.71-1.15; P = .42 for interaction). More intensive LDL-C-lowering statin-based therapies were associated with a reduced risk of major cardiovascular events, but with an increased risk of hemorrhagic stroke, compared with less intensive LDL-C-lowering statin-based therapies. More intensive LDL-C-lowering statin-based therapies were associated with a reduced risk of recurrent stroke in trials with all patients having evidence of atherosclerosis (RR, 0.79; 95% CI, 0.69-0.91), but not in trials with most patients not having evidence of atherosclerosis (RR, 0.95; 95% CI, 0.85-1.07; P = .04 for interaction), compared with less intensive LDL-C-lowering statin-based therapies. CONCLUSIONS AND RELEVANCE: This study suggests that the benefits and risks of more intensive LDL-C-lowering statin-based therapies for recurrent stroke risk reduction might be more favorable than the benefits and risks of less intensive LDL-C-lowering statin-based therapies, especially for patients with evidence of atherosclerosis.
引用
- Lee M, Cheng CY, Wu YL, et al. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials. JAMA Neurol. 2022. PMID: 35188949. doi:10.1001/jamaneurol.2021.5578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。